List of Excipients in Branded Drug NEXLETOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Esperion Therapeutics Inc	NEXLETOL	bempedoic acid	72426-118	HYDROXYPROPYL CELLULOSE	2040-06-19
Esperion Therapeutics Inc	NEXLETOL	bempedoic acid	72426-118	LACTOSE MONOHYDRATE	2040-06-19
Esperion Therapeutics Inc	NEXLETOL	bempedoic acid	72426-118	MAGNESIUM STEARATE	2040-06-19
Esperion Therapeutics Inc	NEXLETOL	bempedoic acid	72426-118	MICROCRYSTALLINE CELLULOSE 101	2040-06-19
Esperion Therapeutics Inc	NEXLETOL	bempedoic acid	72426-118	POLYETHYLENE GLYCOL	2040-06-19
Esperion Therapeutics Inc	NEXLETOL	bempedoic acid	72426-118	POLYVINYL ALCOHOL	2040-06-19
Esperion Therapeutics Inc	NEXLETOL	bempedoic acid	72426-118	SILICON DIOXIDE	2040-06-19

NEXLETOL Excipient Strategy and Commercial Opportunities for Bempedoic Acid

Last updated: August 2, 2026

NEXLETOL is an oral, immediate-release bempedoic acid tablet approved by the FDA to reduce low-density lipoprotein cholesterol and, following label expansion, reduce major cardiovascular events in selected patients who cannot use recommended statin therapy. Its excipient platform is conventional and reproducible, which lowers manufacturing complexity but creates limited differentiation for suppliers competing only on standard tablet ingredients. The strongest commercial opportunities are in bioequivalence-enabling formulations, direct-compression improvements, low-lactose or lactose-free alternatives, coating systems, and fixed-dose combinations with ezetimibe.

What is NEXLETOL and which formulation does it use?

NEXLETOL contains 180 mg of bempedoic acid in a film-coated, immediate-release tablet. Esperion Therapeutics developed and commercializes the product in the United States, with regional commercialization partners outside the United States.

Bempedoic acid is an ATP-citrate lyase inhibitor. It is activated primarily in the liver and has limited activation in skeletal muscle, which supports its use in patients who are unable to tolerate adequate statin therapy. NEXLETOL is administered orally once daily, with or without food [1].

NEXLETOL formulation profile

Attribute	NEXLETOL profile
Active ingredient	Bempedoic acid
Strength	180 mg
Dosage form	Film-coated immediate-release tablet
Route	Oral
Administration	Once daily
FDA initial approval	February 2020
Primary use	LDL-cholesterol lowering
Cardiovascular indication	Reduction of major cardiovascular events in specified high-risk patients
Combination product	NEXLIZET, bempedoic acid 180 mg plus ezetimibe 10 mg
Product type	Small-molecule drug
Biosimilar pathway	Not applicable

The product does not depend on a complex delivery system, modified-release mechanism, lipid nanoparticle, biologic carrier, or device. That simplifies scale-up and generic development.

What excipients are used in NEXLETOL tablets?

The U.S. prescribing information identifies a conventional tablet core containing lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. The film coating contains standard coating materials, including hypromellose, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, iron oxide, and FD&C Blue No. 2 aluminum lake, according to the product labeling [1].

NEXLETOL excipient functions

Excipient	Primary formulation function	Commercial relevance
Lactose monohydrate	Diluent and tablet-mass builder	Creates opportunity for lactose-free or low-lactose alternatives
Microcrystalline cellulose	Diluent, compressibility aid	Important for direct compression and tablet hardness
Hydroxypropyl cellulose	Binder	Supports granulation and mechanical strength
Sodium starch glycolate	Superdisintegrant	Supports immediate release
Colloidal silicon dioxide	Glidant and flow aid	Relevant to powder-flow optimization
Magnesium stearate	Lubricant	Requires control because excess levels can slow dissolution
Hypromellose	Film former	Standard coating platform
Polyethylene glycol	Plasticizer and coating aid	Used to improve coating flexibility
Polyvinyl alcohol	Film-forming polymer	Supports aqueous coating systems
Talc	Anti-tacking and coating aid	Controls coating process performance
Titanium dioxide and iron oxide	Opacifying and coloring agents	Supports product identity and light protection
FD&C Blue No. 2 aluminum lake	Colorant	Supports visual differentiation

The formulation is commercially accessible to generic manufacturers because the excipient set is widely available from established suppliers. The principal development challenge is not unusual excipient chemistry. It is achieving comparable dissolution, tablet robustness, coating appearance, impurity control, and stability at commercial scale.

What excipient strategy is most appropriate for NEXLETOL?

The current NEXLETOL formulation supports a low-risk immediate-release strategy rather than a platform requiring novel excipient qualification.

Direct compression versus wet granulation

A generic or lifecycle formulation developer can evaluate direct compression using co-processed microcrystalline cellulose, lactose, mannitol, or dibasic calcium phosphate. Direct compression may reduce processing steps, solvent exposure, energy use, and manufacturing cost.

The principal technical risks are:

• Poor powder flow caused by the active pharmaceutical ingredient or fine excipient fractions.
• Segregation between bempedoic acid and high-load diluents.
• Over-lubrication from magnesium stearate.
• Tablet capping or lamination at high compression force.
• Dissolution changes after scale-up.
• Color and coating variation across large batches.

Wet granulation may provide better content uniformity and flow if the active ingredient has unfavorable bulk properties. It also creates a more complex process and can increase development costs. A supplier offering high-functionality excipients can compete by demonstrating equivalent dissolution with fewer processing steps.

Lactose-free and low-lactose opportunities

Lactose is a major commercial target because some patients avoid lactose-containing medicines and some manufacturers seek a simplified excipient declaration. A lactose-free alternative could replace lactose monohydrate with:

• Microcrystalline cellulose;
• Mannitol;
• Dibasic calcium phosphate;
• Pregelatinized starch;
• Spray-dried cellulose-based systems; or
• Co-processed cellulose and starch platforms.

A lactose-free formulation would require comparative dissolution, stability, tablet hardness, friability, disintegration, and bioequivalence testing. The commercial value is likely incremental rather than transformative because the existing tablet is already orally convenient and does not carry a major excipient-related warning.

Low-magnesium-stearate formulations

Magnesium stearate is inexpensive and widely accepted, but it can reduce wettability and slow dissolution when used at excessive concentrations or mixed for too long. Alternative lubricants, including sodium stearyl fumarate, may support more consistent dissolution in direct-compression formulations.

The opportunity is strongest where a developer can use a lower lubricant concentration, shorten blending time, or improve robustness without changing the tablet’s dissolution profile.

Coating-system opportunities

NEXLETOL uses a conventional film coat. Commercial suppliers can compete with:

• Ready-to-use aqueous coating systems;
• Lower-titanium-dioxide or titanium-dioxide-free systems;
• Improved color matching;
• Lower coating weight;
• Faster drying systems;
• Enhanced moisture-barrier coatings; and
• Coatings optimized for continuous manufacturing.

Coating changes are unlikely to create meaningful clinical differentiation, but they can reduce manufacturing cost and improve supply reliability. A supplier that can match the blue tablet appearance while reducing process time may have a practical advantage with generic manufacturers and contract development and manufacturing organizations.

What formulation patents protect NEXLETOL?

NEXLETOL’s core commercial protection is centered primarily on bempedoic acid, pharmaceutical compositions, and therapeutic methods rather than on a highly distinctive excipient platform. The conventional nature of the tablet means that excipient substitution may be possible, subject to product-specific equivalence and patent analysis.

Patent protection must be separated into four categories:

1. Composition-of-matter patents covering bempedoic acid or related compounds.
2. Pharmaceutical composition patents covering formulations or dosage forms.
3. Method-of-use patents covering LDL lowering, statin-intolerant populations, or cardiovascular risk reduction.
4. Combination-product patents covering bempedoic acid with ezetimibe.

The FDA Orange Book is the controlling source for patents listed against NEXLETOL and NEXLIZET. Patent listings and expiration dates can change through delisting, regulatory updates, pediatric extensions, terminal disclaimers, or litigation outcomes [2].

How does NEXLETOL patent risk affect excipient suppliers?

Excipient suppliers do not generally bear the principal Paragraph IV risk. That risk falls on the ANDA applicant and its legal advisers. Suppliers can still affect that risk through:

• Formulation design-around support;
• Documentation showing that an excipient is non-infringing;
• Control of proprietary grades;
• Freedom-to-operate analysis for co-processed systems;
• Support for alternative coating formulations; and
• CMC packages that reduce the need to copy the reference product.

A generic applicant may prefer a formulation that uses the same broad excipient classes but different grades, ratios, manufacturing steps, or coating materials. The commercial opportunity is strongest when the supplier can provide technical performance without creating dependency on the reference product’s exact qualitative and quantitative composition.

When does NEXLETOL lose regulatory exclusivity?

NEXLETOL received FDA approval in February 2020. Bempedoic acid received new chemical entity protection associated with the initial approval, creating a five-year period during which an ANDA relying on the reference product generally could not be filed, subject to statutory exceptions. That period reached its nominal endpoint in February 2025 [1, 3].

Regulatory exclusivity is separate from patent protection. The end of NCE exclusivity does not establish generic launch freedom. Patent claims, Paragraph IV litigation, 30-month stays, settlements, pediatric extensions, and other listed protections can control actual market entry.

NEXLIZET is a separate fixed-dose combination containing bempedoic acid and ezetimibe. Its regulatory and patent analysis must be conducted independently from NEXLETOL.

What generic entry risks exist for NEXLETOL?

NEXLETOL is a conventional small-molecule tablet, so it is structurally more exposed to ANDA competition than a biologic or complex injectable product. The likely generic pathway is an ANDA demonstrating pharmaceutical equivalence and bioequivalence.

Key generic development issues

Development issue	Risk level	Commercial implication
Tablet composition	Moderate	Conventional excipients allow multiple design options
Dissolution matching	Moderate	Magnesium stearate, particle size, and disintegrant level can affect release
Content uniformity	Moderate	Relevant if the active has poor flow or segregation risk
Stability	Moderate	Requires control of moisture, impurities, and coating performance
Bioequivalence	Moderate	Immediate-release dosage form generally simplifies clinical development
Patent certification	High	Determines filing and launch timing
Manufacturing scale-up	Moderate	Coating and blending are manageable but require process control
Biosimilar complexity	None	Bempedoic acid is not a biologic

A first-filer Paragraph IV applicant could obtain 180-day exclusivity if statutory conditions are met. A successful challenge could create a rapid price decline after launch, while a settlement could defer entry and preserve value for the branded product.

What is the FDA status of NEXLETOL?

The FDA approved NEXLETOL in 2020 for LDL-cholesterol reduction in adults with established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who require additional lowering of LDL cholesterol. The FDA later expanded the label to include reduction of major cardiovascular events in eligible adults who cannot take recommended statin therapy [1].

The label expansion followed the CLEAR Outcomes trial, which enrolled statin-intolerant patients and showed a reduction in major cardiovascular events with bempedoic acid relative to placebo [4]. This broader outcome-based indication increases the product’s commercial value beyond a conventional LDL-lowering positioning.

How does NEXLETOL compare with NEXLIZET?

Attribute	NEXLETOL	NEXLIZET
Active ingredients	Bempedoic acid	Bempedoic acid plus ezetimibe
Bempedoic acid dose	180 mg	180 mg
Ezetimibe dose	None	10 mg
Product strategy	Single-agent therapy	Fixed-dose combination
Excipient complexity	Lower	Higher because of two active ingredients
Generic development	Conventional ANDA pathway	Combination-product development
Commercial positioning	Add-on or alternative LDL lowering	Greater LDL reduction through dual mechanism
Formulation opportunity	Tablet optimization	Content uniformity, dissolution, and dual-API compatibility

NEXLIZET offers greater formulation complexity and may provide more opportunities for differentiated excipient systems. Its developers must control interaction risks between bempedoic acid, ezetimibe, lubricants, disintegrants, and moisture. That complexity can create a higher barrier to generic development than NEXLETOL alone.

Which companies are commercializing or challenging NEXLETOL?

Esperion is the principal U.S. commercial company. The company has pursued regional partnerships and licensing arrangements for bempedoic acid products, including agreements involving Daiichi Sankyo and Menarini in international markets [5].

The competitive landscape includes:

• High-intensity and moderate-intensity statins;
• Ezetimibe;
• PCSK9 monoclonal antibodies such as evolocumab and alirocumab;
• Inclisiran;
• Bempedoic acid products;
• Combination products such as NEXLIZET; and
• Future authorized or independent generic versions.

NEXLETOL’s commercial differentiation depends on statin intolerance, oral administration, cardiovascular outcomes data, and use in patients who need additional LDL reduction without another injectable therapy.

What commercial opportunities exist for excipient manufacturers?

The strongest opportunities are practical rather than proprietary.

High-value opportunity areas

1. Lactose-free reformulation platforms. Suppliers can replace lactose while preserving tablet weight, hardness, disintegration, and dissolution.

2. Direct-compression systems. Co-processed excipients can reduce granulation requirements and improve powder flow.

3. Dissolution-control packages. Suppliers can optimize disintegrant, lubricant, and wetting behavior to match the reference product.

4. Film-coating systems. Ready-to-use aqueous coatings can reduce batch time and improve color consistency.

5. Continuous-manufacturing excipients. Narrow particle-size distributions and predictable flow can support continuous blending and compression.

6. Global regulatory packages. Excipient suppliers with DMF support, compendial data, elemental-impurity assessments, and nitrosamine evaluations can improve customer adoption.

7. NEXLIZET development support. Dual-API formulation work offers greater technical value than NEXLETOL generic substitution alone.

Revenue potential will depend on generic launch timing, the number of ANDA applicants, tablet volume, and the extent of price erosion. Standard excipients will face intense price competition. Specialty co-processed systems and technical services can command higher margins because they influence development speed and bioequivalence risk.

What manufacturing and intellectual-property barriers matter most?

The principal barriers are regulatory and commercial rather than raw-material availability. Bempedoic acid API supply, impurity control, analytical reference standards, dissolution matching, patent certification, and manufacturing scale-up are more important than access to the listed excipients.

A supplier with a proprietary excipient grade may obtain limited formulation differentiation, but excipient patents rarely provide the same protection as active-ingredient or method-of-use patents. Commercial defensibility is more likely to come from validated performance, regulatory support, supply continuity, and integration into a customer’s development process.

Key Takeaways

• NEXLETOL is a conventional immediate-release bempedoic acid tablet with widely used excipients.
• The current excipient platform includes lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate, plus a standard film coat.
• The best excipient opportunities are lactose-free reformulation, direct compression, dissolution optimization, and ready-to-use coating systems.
• Bempedoic acid’s five-year NCE exclusivity reached its nominal endpoint in February 2025, but patent and litigation status determines actual generic entry.
• NEXLIZET provides a more technically complex and potentially more defensible formulation opportunity because it contains two active ingredients.
• Bempedoic acid is a small molecule, so biosimilar competition does not apply. Generic competition through the ANDA pathway is the relevant risk.
• Excipient suppliers should compete through bioequivalence support, regulatory documentation, process performance, and supply reliability rather than commodity pricing alone.

FAQs

Can NEXLETOL be reformulated without lactose?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, pregelatinized starch, or co-processed excipients. The reformulated product would need to demonstrate acceptable pharmaceutical performance and bioequivalence where required.

Is NEXLETOL an extended-release tablet?

No. NEXLETOL is an immediate-release, once-daily film-coated tablet.

Does NEXLETOL require a biosimilar application?

No. Bempedoic acid is a small-molecule active ingredient. A follow-on product would generally use the ANDA pathway rather than the biosimilar pathway.

Is NEXLIZET a stronger excipient opportunity than NEXLETOL?

Yes, from a technical-development perspective. The dual-API formulation creates more complex requirements for blend uniformity, dissolution, stability, and drug-excipient compatibility.

Can an excipient supplier obtain patent protection around a NEXLETOL reformulation?

Potentially, if the reformulation contains a genuinely novel and non-obvious composition or manufacturing process. Patentability is more difficult for routine substitution of lactose, magnesium stearate, or standard coating materials.

References

1. U.S. Food and Drug Administration. (2024). Nexletol (bempedoic acid) prescribing information.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). New chemical entity exclusivity and regulatory exclusivity provisions.
4. Nissen, S. E., Lincoff, A. M., Brennan, D., et al. (2023). Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine, 388(14), 1353-1364.
5. Esperion Therapeutics, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023.